Drugs / PF-06291874
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01856595 | May 2013 → Jan 2014 | type 2 diabetes mellitus | Pfizer | Completed | Mixed |
| Phase 1 | NCT01794364 | Jan → Mar 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01499017 | Nov 2011 → Jan 2012 | — | Pfizer | Terminated | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02554877 | Oct 2015 → Aug 2016 | type 2 diabetes mellitus | Pfizer | Completed | Met primary |
| Phase 2 | NCT02175121 | Aug 2014 → Mar 2015 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06291874 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01856595 ↗ |
| Action | Inhibit | “Glucagon receptor antagonist” CHEMBL2381848 ↗ |
| Modality | Small molecule | — CHEMBL2381848 ↗ |
| Route | Oral | “single oral doses of PF-06291874 in healthy volunteers.” NCT01499017 ↗ |
| Target | GCGR | “Glucagon receptor antagonist” CHEMBL2381848 ↗ |